Over the past few years, biotech startups have been successful at raising large amounts of capital just as they’re starting out. It has led to a lot of unicorns, with multibillion-dollar-valued companies having raised hundreds of millions in their series A or B rounds.
{iframe}http://www.businessinsider.com/what-biotech-venture-capitalists-think-of-massive-early-funding-rounds-2018-1{/iframe}